Monte Rosa Therapeutics Quarterly Income Statement
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Monte Rosa Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Monte Rosa Therapeutics generated $9.0 million in revenue, down 61.3% from the same quarter a year earlier. Monte Rosa Therapeutics reported a net loss of $43.4 million, compared with a loss of $12.3 million a year earlier. Operating margin was -547.8%.
Diluted earnings per share came in at -$0.43.
Summary generated from market data by MetaCap's automated system. Methodology
Monte Rosa Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.97M | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M | 60.65M | 9.22M | 4.70M | 1.06M | 0 | 0 |
| Revenue growth (YoY) | -61.33% | -95.04% | -95.41% | +38.54% | +394.01% | +7882.05% | — | — | — | — | — | — |
| Operating Expenses | 58.10M | 54.24M | 52.50M | 45.74M | 38.75M | 40.89M | 47.64M | 35.74M | 37.34M | 36.01M | 34.86M | 36.97M |
| Research & Development | 47.96M | 44.07M | 41.98M | 36.68M | 30.65M | 32.19M | 38.87M | 27.62M | 28.05M | 27.03M | 27.14M | 28.31M |
| Operating Income | -49.13M | -50.03M | -49.72M | -32.98M | -15.55M | 44.04M | 13.00M | -26.53M | -32.64M | -34.95M | -34.86M | -36.97M |
| Other Income (Expense) | 5.94M | 5.58M | 3.64M | 2.72M | 4.46M | 3.67M | 2.60M | 2.74M | 2.58M | 3.06M | 1.59M | 2.25M |
| Pretax Income | -43.19M | -44.45M | -46.08M | -30.26M | -11.10M | 47.71M | 15.60M | -23.79M | -30.06M | -31.89M | -33.27M | -34.71M |
| Income Tax | 208.00K | 52.00K | 59.00K | -3.18M | 1.20M | 822.00K | 2.16M | 71.00K | 252.00K | 83.00K | -22.00K | 170.00K |
| Net Income | -43.40M | -44.50M | -46.11M | -27.08M | -12.29M | 46.88M | 13.44M | -23.86M | -30.31M | -31.97M | -33.25M | -34.88M |
| Net Income growth (YoY) | — | -194.92% | -443.15% | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.43 | -0.45 | -0.55 | -0.33 | -0.15 | 0.57 | 0.27 | -0.29 | -0.43 | -0.53 | -0.57 | -0.70 |
| EPS (Diluted) | -0.43 | -0.45 | -0.55 | -0.33 | -0.15 | 0.57 | 0.27 | -0.29 | -0.43 | -0.53 | -0.57 | -0.70 |
| Shares Outstanding (Basic) | 101.48M | 99.88M | — | 82.40M | 82.19M | 82.15M | — | 82.01M | 71.23M | 60.16M | — | 49.81M |
| Shares Outstanding (Diluted) | 101.48M | 99.88M | — | 82.40M | 82.19M | 82.96M | — | 82.01M | 71.23M | 60.16M | — | 49.81M |
| EBITDA | -47.22M | -48.01M | -47.63M | -30.88M | -13.43M | 46.08M | 15.06M | -24.42M | -30.58M | -33.05M | -33.02M | -35.13M |
| Operating Margin | -547.84% | -1188.46% | -1787.67% | -258.26% | -67.06% | 51.85% | 21.44% | -287.84% | -695.25% | -3284.49% | — | — |
| Net Margin | -483.91% | -1057.08% | -1658.00% | -212.10% | -53.01% | 55.20% | 22.16% | -258.89% | -645.58% | -3004.51% | — | — |
This table shows 12 quarterly periods of Monte Rosa Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow GLUE's reporting calendar. What is a income statement?